{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:12:17Z","timestamp":1787238737586,"version":"build-2736575974"},"reference-count":18,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder characterised by distinct radiological features. Common precipitants of this disorder include acute medical illness, hypertensive crisis, eclampsia, immunosuppressive therapy and chemotherapy. We present the case of a patient with advanced ovarian carcinoma who developed PRES shortly after receiving bevacizumab (Avastin), an inhibitor of vascular endothelial growth factor. The patient's medical history and clinical presentation both suggest bevacizumab as the precipitator for PRES. This agent has been often overlooked as a possible cause of this rare neurological syndrome.<\/jats:p>","DOI":"10.1136\/bcr-2012-007995","type":"journal-article","created":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T01:56:39Z","timestamp":1361498199000},"page":"bcr2012007995","source":"Crossref","is-referenced-by-count":20,"title":["Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient"],"prefix":"10.1136","volume":"2013","author":[{"given":"Ola","family":"Abbas","sequence":"first","affiliation":[{"name":"Department of Anaesthesia, Royal Oldham Hospital, Peninne Acute Hospitals Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shamseddin","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Temraz","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Haydar","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,2,21]]},"reference":[{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340803"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcr139"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.3","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A0928"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.9991"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.5","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A0929"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.6","doi-asserted-by":"publisher","DOI":"10.1179\/016164106X110346"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.7","doi-asserted-by":"publisher","DOI":"10.1159\/000086127"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0895-x"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07629.x"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2011.08.018"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.11","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(89)90125-2"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/107327480701400312","article-title":"Spectrum of activity and mechanism of action of VEGF\/PDGF inhibitors","volume":"14","author":"Homsi","year":"2007","journal-title":"Cancer Control"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.13","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1987"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.15","unstructured":"BC Cancer Agency. Cancer management guidelines: management guidelines of bevacizumab-related side effects. British Columbia, Canada. 2006 ."},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052954"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn637"},{"key":"2025082701362044000_2013.feb21_1.bcr2012007995.18","unstructured":"Genentech, Inc. Avastin prescribing information. http:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf (accessed 5 Feb 2012)."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2012-007995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:36:32Z","timestamp":1756283792000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2012-007995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,21]]},"references-count":18,"alternative-id":["10.1136\/bcr-2012-007995"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2012-007995","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,21]]}}}